JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
For this product you will need: BACTERIOSTATIC WATER For reconstitution.
Fragment 176-191, also known as AOD9604, is a synthetic peptide of the C-terminus of human growth hormone. This peptide fragment is functionally different from the hormone in its structure, and is used in laboratory research to probe protein conformation, receptor binding and signalling pathways, typically in the presence of experimental inhibitors or as a means for targeting a specific cellular population.
Due to limited published literature, current investigations primarily focus on comparative structural behaviour, pathway engagement, and molecular stability relative to other growth hormone–derived fragments. Fragment 176–191 is classified as a research compound and has not been approved by the FDA. At Element CRP, Fragment 176–191 for sale is supplied exclusively for laboratory and educational research use by qualified researchers.
From Pubchem
Synonyms: 66004-57-7, Hgh (176-191), DTXSID10216216Molecular Formula: C78H123N23O22S2Molecular Weight: 1799.1 g/molCAS Number: 66004-57-7PubChem CID: 16131230
Experimental studies using animal models have examined lipolytic fragments derived from the C-terminal region of human growth hormone for their role in lipid-associated molecular signalling pathways. In one investigation involving obese Zucker rats, subjects received AOD9604 at 500 µg/kg body weight or placebo for 19 days.
Analytical observations from this study described differences in weight-gain trajectories between experimental and control groups, positioning this peptide fragment as a reference molecule for metabolic signalling research under controlled laboratory conditions [1].
Additional studies conducted in obese mouse models evaluated AOD9604 exposure over a 14-day period. These investigations reported changes in body composition parameters alongside altered expression of beta-3 adrenergic receptors within adipose-associated cellular frameworks.
Further analysis indicated that signalling responses were dependent on receptor presence, as receptor-deficient models did not exhibit comparable molecular changes. These findings are interpreted strictly within pathway-characterisation and receptor-dependence research contexts [2].
Research has also explored the interaction of human growth hormone fragments, including 176–191, with glucose-associated molecular signalling pathways. Comparative analytical studies assessed multiple GH-derived fragments to examine their relative influence on intracellular signalling intermediates related to glucose handling.
Among the fragments evaluated, 176–191 demonstrated notable pathway-level interaction profiles. These observations were associated with measured changes in insulin-adjacent signalling markers and cellular glucose-processing parameters, without attribution to physiological or functional outcomes [3].
Experimental literature has referenced the C-terminal fragment of human growth hormone in studies examining signalling pathways associated with cartilage-adjacent cellular environments. In one rabbit model of knee osteoarthritis, AOD9604 was evaluated with and without hyaluronic acid using intra-articular experimental administration.
Comparative groups received saline, hyaluronic acid, AOD9604, or a combination of AOD9604 and hyaluronic acid. Analytical outcomes described differences in cartilage-associated structural markers and matrix-related signalling responses under controlled experimental conditions [4].
Frag 176–191 is a peptide fragment derived from the C-terminal region of the human growth hormone sequence. Existing studies reference this fragment in the context of lipid-associated signalling, glucose-related molecular pathways, and cartilage-adjacent experimental models.
Frag 176–191 is classified strictly as a research molecule. It is intended solely for laboratory and academic investigation and is not approved for human or animal use. No clinical, diagnostic, therapeutic, or consumptive applications are stated or implied.
Element CRP supplies Frag 176–191 exclusively for qualified research professionals conducting controlled analytical investigations.
Fragment 176-191 is a synthetic 16-amino-acid peptide corresponding to the C-terminal region of human growth hormone, retaining the lipolytic activity domain while excluding the regions responsible for IGF-1 axis engagement. Its truncated structure supports stable behaviour in standard cell culture buffer systems used for adipocyte cell biology research.
Cell-based research with Fragment 176-191 examines its activity in lipolysis pathway studies using 3T3-L1 adipocyte models and primary adipocyte cell preparations. Standard functional readouts measure glycerol release, fatty acid mobilisation, and downstream signalling through hormone-sensitive lipase phosphorylation in cell-based assay formats.
Element CRP supplies this product at 5mg per vial. USA-manufactured via solid-phase peptide synthesis and verified at 99%+ purity by HPLC and Mass Spectrometry. Reconstitution with bacteriostatic water required. Store lyophilised at -20°C; stable for 24 months.
WARNING: For research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
